Lenalidomide Capsules
Treats multiple myeloma, myelodysplastic syndromes and certain lymphomas by modulating the immune system and directly targeting tumour cells, resulting in reduced cancer cell proliferation.
- Category
- Oncology Support
- Active ingredient
- Lenalidomide
- Route
- Oral use
- Form
- Capsule, hard
- Strengths
- 10mg
The exact manufacturer offered is confirmed by the fulfilment partner before supply.
Prescription and consultation requirements for Lenalidomide Capsules vary by destination and are determined by the fulfilment partner.
Lenalidomide Capsules details
- Conditions
- Multiple Myeloma as Monotherapy for Maintenance Treatment After Autologous Stem Cell Transplantation · Multiple Myeloma as Combination Therapy with Dexamethasone for Patients with Previously Untreated Disease Who Are Not Eligible for Transplant · Multiple Myeloma as Combination Therapy with Bortezomib and Dexamethasone for Patients with Previously Untreated Disease Who Are Not Eligible for Transplant · Multiple Myeloma as Combination Therapy with Melphalan and Prednisone for Patients with Previously Untreated Disease Who Are Not Eligible for Transplant · Multiple Myeloma as Monotherapy for Treatment After At Least One Prior Therapy · Transfusion-dependent Anaemia Due to Low or Intermediate-1 Risk Myelodysplastic Syndromes Associated with Isolated Deletion 5q Cytogenetic Abnormality When Other Therapeutic Options Are Insufficient or Inadequate · Mantle Cell Lymphoma in Adult Patients with Relapsed or Refractory Disease · Follicular Lymphoma in Combination with Rituximab in Adult Patients with Previously Treated Disease · Marginal Zone Lymphoma in Combination with Rituximab in Adult Patients with Previously Treated Disease
- Alternative names
- Revlimid
- Therapeutic class
- Immunosuppressants; Other immunosuppressants
- Pharmacological class
- Immunomodulatory imide drug; Cereblon e3 ubiquitin ligase modulator
- Dosage forms
- Capsule, hard
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Storage instructions
- Store below 25°C. Keep in the original blister package to protect from moisture.
Known off-label uses
primary central nervous system lymphoma; systemic light chain amyloidosis; myelofibrosis; myelodysplastic syndromes without del 5q
Contraindications
hypersensitivity to lenalidomide or any excipient; women who are pregnant; women of childbearing potential unless all conditions of the pregnancy prevention programme are met
Precautions and warnings
pregnancy prevention programme mandatory for all patients; haematological toxicity including neutropenia and thrombocytopenia requiring regular monitoring; venous thromboembolism risk particularly in combination with dexamethasone requiring thromboprophylaxis; second primary malignancies including acute myeloid leukaemia and myelodysplastic syndromes; thyroid disorders including hypothyroidism and hyperthyroidism; peripheral neuropathy; tumour flare reaction and tumour lysis syndrome; cardiac disorders including myocardial infarction and cardiac failure; hepatic disorders including hepatic failure; severe cutaneous reactions including stevens-johnson syndrome and toxic epidermal necrolysis; allergic reactions including angioedema; caution in patients with renal impairment requiring dose adjustment; caution in patients with hepatic impairment; contains lactose; contains sodium; males must use condoms during treatment and for 4 weeks after discontinuation
Minor side effects
neutropenia; thrombocytopenia; anaemia; fatigue; diarrhoea; constipation; nausea; vomiting; decreased appetite; pyrexia; peripheral oedema; muscle cramps; muscle spasms; back pain; arthralgia; pain in extremity; headache; dizziness; tremor; dyspnoea; cough; epistaxis; upper respiratory tract infection; pneumonia; rash; pruritus; dry skin; insomnia; depression; anxiety; blurred vision; dysgeusia; asthenia; weight decreased; hypokalaemia; hypocalcaemia
Moderate side effects
febrile neutropenia; severe thrombocytopenia with bleeding; deep vein thrombosis; pulmonary embolism; acute myeloid leukaemia; myelodysplastic syndromes; myocardial infarction; cardiac failure; atrial fibrillation; stevens-johnson syndrome; toxic epidermal necrolysis; angioedema; hepatic failure; tumour lysis syndrome; sepsis; pneumonia; progressive multifocal leukoencephalopathy; pancreatitis; hepatitis b reactivation; acute kidney injury; gastrointestinal perforation
Serious side effects
signs of venous thromboembolism including sudden chest pain, difficulty breathing, swelling or pain in one leg, requires immediate medical attention; signs of severe infection including high fever, chills, confusion, severe cough, requires immediate medical attention; signs of severe cutaneous reactions including widespread rash, blistering, peeling skin, requires immediate medical attention; signs of myocardial infarction including chest pain, shortness of breath, pain radiating to arm or jaw, requires immediate medical attention; signs of tumour lysis syndrome including muscle cramps, irregular heartbeat, decreased urination, requires immediate medical attention; signs of angioedema including swelling of face, lips, tongue or throat, requires immediate medical attention; signs of hepatic failure including jaundice, dark urine, confusion, abdominal swelling, requires immediate medical attention
Patient summary
Treats multiple myeloma, myelodysplastic syndromes and certain lymphomas by modulating the immune system and directly targeting tumour cells, resulting in reduced cancer cell proliferation.
Mechanism of action
Lenalidomide is a medicine related to thalidomide that affects the immune system and directly attacks cancer cells. It works by binding to a protein called cereblon inside cells, which changes how the cell functions. In cancer cells, this triggers their destruction and stops them from multiplying. In immune cells, it helps the body's natural defences recognise and fight the cancer. It also blocks the growth of new blood vessels that tumours need to survive. These combined actions help control cancers of the blood and bone marrow.
Drug interactions
dexamethasone; melphalan; bortezomib; rituximab; warfarin; apixaban; rivaroxaban; dabigatran; heparin; enalapril; ramipril; lisinopril; digoxin; simvastatin; atorvastatin; rosuvastatin; erythropoiesis-stimulating agents; hormonal contraceptives
Age restrictions
Safety and efficacy in children and adolescents below 18 years have not been established.
Pregnancy and breastfeeding
Lenalidomide is contraindicated during pregnancy. It is structurally related to thalidomide and is expected to cause severe life-threatening birth defects. Women of childbearing potential must use effective contraception from at least 4 weeks before treatment, during treatment, and for at least 4 weeks after stopping. Breast-feeding must be discontinued during therapy.
What you will receive
Lenalidomide Capsules is a generic medicine sold under the name of its active ingredient, Lenalidomide, rather than under a brand.
- The fulfilment partner confirms the offered manufacturer and product before supply.
- Check the active ingredient, strength, form and pack shown at checkout before confirming an order.